Evaluation of serum osteoprotegerin and fetuin A levels in Egyptian patients with chronic kidney disease

被引：0
作者：
Nessim I.G. [1 ]
el Wahab A.A. [4 ]
Madani H.A. [4 ]
Waked E. [2 ]
el Khalek A.A. [3 ]
Mabrouk K. [1 ]
机构：
[1] Clinical Chemistry, Theodor Bilharz Research Institute, Giza
[2] Nephrology, Theodor Bilharz Research Institute, Giza
[3] Intensive care medicine, Theodor Bilharz Research Institute, Giza
[4] Clinical and Chemical pathology, Faculty of Medicine, Cairo University, Cairo
来源：
Comparative Clinical Pathology | 2011年 / 20卷 / 5期
关键词：
CKD; Fetuin A; Osteoprotegerin; Vascular calcification;
D O I：
10.1007/s00580-011-1281-9
中图分类号：
学科分类号：
摘要：
Vascular calcifications are recognized as important risk factors for uremia-induced cardiovascular disease. Yet some patients with chronic kidney disease (CKD) do not develop calcification despite exposure to the same uremic conditions. Physiological inhibitors of calcification such as fetuin A, which is an extraosseous calcification inhibitor, and osteoprotegerin (OPG), which is a regulator of bone resorption, may prevent the development and progression of vascular calcification. The aim of this work is to study the serum levels of fetuin A and OPG to understand their role in vascular calcification in patients with chronic renal impairment. A total of 80 subjects (60 CKD patients and 20 age- and sex-matched healthy controls) were studied. Fetuin A and osteoprotegerin were measured by ELISA; in addition to standard biochemical analysis, ECG and echocardiography were done to evaluate cardiovascular calcification. Fetuin A levels were significantly lower; OPG levels were significantly higher in the patients group compared to the controls. There was an inverse association between fetuin A and vascular calcifications in the patients group (P = -0. 498, r = -0. 001), while OPG showed a positive association (P = 0. 510, r = 0. 003). Serum fetuin A and osteoprotegerin levels were related to vascular calcification in CKD stages III, IV, and V. Decreased serum fetuin A may have a role in enhancing the cardiovascular morbidity and mortality in those patients by promoting a process of accelerated vascular calcification; elevated serum OPG levels increase with the progression of CKD, so these can be used as markers in the follow-up of those patients. © 2011 Springer-Verlag London Limited.
引用
收藏
页码：421 / 425
页数：4
相关论文
共 31 条
[1]  
Bargnoux A.S., Dupuy A.M., Garrigue V., Deleuze S., Cristol J.P., Mourad G., Renal transplantation decreases osteoprotegerin levels, Transplant Proc, 38, pp. 2317-2318, (2006)
[2]  
Block G.A., Spiegel D.M., Ehrlich J., Et al., Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis, Kidney Int, 68, pp. 1815-1824, (2005)
[3]  
Boyle W.J., Simonet W.S., Lacey D.L., Osteoclast differentiation and activation, Nature, 423, pp. 337-342, (2003)
[4]  
Caglar K., Yilmaz M.I., Saglam M., Cakir E., Kilic S., Sonmez A., Eyileten T., Yenicesu M., Oguz Y., Tasar M., Vural A., Ikizler T.A., Stenvinkel P., Lindholm B., Serum fetuin-A concentration and endothelial dysfunction in chronic kidney disease, Nephron Clin Pract, 108, pp. 233-240, (2008)
[5]  
Coen G., Ballanti P., Balducci A., Calabria S., Fischer M.S., Jankovic L., Manni M., Morosetti M., Moscaritolo E., Sardella D., Bonucci E., Serum osteoprotegerin and renal osteodystrophy, Nephrol Dial Transplant, 17, pp. 233-238, (2002)
[6]  
Cottone S., Palermo A., Arsena R., Riccobene R., Guarneri M., Mule G., Et al., Relationship of fetuin-A with glomerular filtration rate and endothelial dysfunction in moderate-severe chronic kidney disease, Jnephrol, 23, 1, pp. 62-69, (2010)
[7]  
Cozzolino M., Biondi M.L., Galassi A., Et al., Gene polymorphisms and serum alpha-2-Heremans-Schmid levels in Italian haemodialysis patients, Am J Nephrol, 27, pp. 639-642, (2007)
[8]  
El-Abbadi M., Giachelli C.M., Mechanisms of vascular calcification, Adv Chronic Kidney Dis, 14, pp. 54-66, (2007)
[9]  
Foley R.N., Parfrey P.S., Sarnak M.J., Clinical epidemiology of cardiovascular disease in chronic renal failure, Am J Kidney Dis, 32, SUPPL. 5, pp. 112-119, (1998)
[10]  
Grzegorzewska A.E., Mlot M., Serum osteoprotegerin level is lower in peritoneal dialysis patients than hemodialysis ones, Rocz Akad Med Bialymst, 49, pp. 193-196, (2004)
1234